PDF
ZENODO
Published
2026-03-13
Section
Articles
How to Cite
How to Cite
LABORATORY ALTERATIONS OF ANEMIA IN THE BACKGROUND OF CHRONIC HEPATITIS B
R.Z. Umurzaqova
Associate Professor, PhD
S.D. Aminbaeva
Master’s Student, 1st Year, Laboratory Work) Department of Hospital Therapy and Endocrinology, Andijan State Medical Institute, Andijan, Uzbekistan.
Keywords: Chronic Hepatitis B, Anemia of chronic disease, Hypersplenism, Portal hypertension, Hemoglobin, Thrombocytopenia, Liver cirrhosis, Ferritin.
Abstract
Anemia is a frequent hematological complication in patients with Chronic Hepatitis B (CHB), significantly impacting their overall prognosis and quality of life. The pathogenesis is multifactorial, primarily involving chronic systemic inflammation, hypersplenism secondary to portal hypertension, and impaired hepatic synthesis of hematopoietic factors. A retrospective cross-sectional study was conducted involving 100 participants. The main group comprised 70 patients with confirmed CHB presenting with anemic syndrome, while the control group included 30 healthy, age-matched individuals. Comprehensive laboratory assessments included complete blood counts, biochemical liver function tests, and iron profiles. Statistical analysis was performed using the Student’s t-test and chi-square test. The results demonstrated that patients with CHB exhibited significant hematological disruptions. The mean hemoglobin level was markedly reduced in the CHB group (94 ± 8.5 g/L) compared to controls (138 ± 10.2 g/L, p < 0.001). Additionally, concomitant thrombocytopenia (115 ± 18 x 10^9/L vs. 250 ± 22 x 10^9/L, p < 0.01) and leukopenia were prevalent, strongly correlating with signs of hypersplenism. Altered iron metabolism, characterized by low transferrin saturation (15 ± 3%) despite normal or elevated ferritin (340 ± 45 mcg/L, p < 0.01), indicated a strong component of anemia of chronic disease. Anemia in CHB is predominantly driven by hypersplenism coupled with chronic inflammatory iron sequestration. Early identification of these specific laboratory patterns is crucial for comprehensive patient management, preventing severe cytopenic complications, and optimizing antiviral therapy.
References
1. World Health Organization. (2021). Global progress report on HIV, viral hepatitis and sexually transmitted infections.
2. Ganne-Carrié, N., & Nahon, P. (2019). Hepatocellular carcinoma in the setting of alcohol-related liver disease. Journal of Hepatology, 70(2), 284-293. DOI: 10.1016/j.jhep.2018.10.008
3. Wigg, A. J., Roberts-Thomson, I. C., Dymock, R. B., McCarthy, P. J., Grose, R. H., & Cummins, A. G. (2020). The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut, 48(2), 206-211. DOI: 10.1136/gut.48.2.206
4. Poordad, F. (2015). Presentation and complications associated with cirrhosis of the liver. Current Medical Research and Opinion, 31(5), 925-930. DOI: 10.1185/03007995.2015.1037728
5. Giannini, E. G., Testa, R., & Savarino, V. (2005). Liver enzyme alteration: a guide for clinicians. CMAJ, 172(3), 367-379. DOI: 10.1503/cmaj.1040752
6. Qiao, Y. F., Chen, S. Q., Peng, Y. W., & Chen, J. (2017). Hematological parameters in chronic hepatitis B patients. Hepatitis Monthly, 17(5), e44876. DOI: 10.5812/hepatmon.44876
7. Weiss, G., & Goodnough, L. T. (2005). Anemia of chronic disease. New England Journal of Medicine, 352(10), 1011-1023. DOI: 10.1056/NEJMra041809
8. Ganz, T. (2013). Systemic iron homeostasis. Physiological Reviews, 93(4), 1721-1741. DOI: 10.1152/physrev.00008.2013
9. McHutchison, J. G., Manns, M. P., Brown, R. S., Reddy, K. R., Shiffman, M. L., & Wong, J. B. (2007). Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. The American Journal of Gastroenterology, 102(4), 880-889. DOI: 10.1111/j.1572-0241.2007.01124.x
10. Sanyal, A. J., Boyer, T., Garcia-Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., ... & Blei, A. (2006). A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology, 134(5), 1360-1368. DOI: 10.1053/j.gastro.2008.02.014
